- Previous Close
1,948.00 - Open
1,948.00 - Bid 1,909.00 x --
- Ask 1,911.00 x --
- Day's Range
1,903.00 - 1,950.00 - 52 Week Range
1,750.00 - 2,360.00 - Volume
48,844 - Avg. Volume
552,589 - Market Cap (intraday)
4.24B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
28.95 - EPS (TTM)
0.66 - Earnings Date Feb 26, 2025
- Forward Dividend & Yield 0.61 (3.14%)
- Ex-Dividend Date Mar 20, 2025
- 1y Target Est
2,442.44
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
www.hikma.com9,500
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HIK.L
View MorePerformance Overview: HIK.L
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HIK.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HIK.L
View MoreValuation Measures
Market Cap
4.32B
Enterprise Value
5.07B
Trailing P/E
29.61
Forward P/E
11.27
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.95
Price/Book (mrq)
2.54
Enterprise Value/Revenue
2.28
Enterprise Value/EBITDA
11.86
Financial Highlights
Profitability and Income Statement
Profit Margin
11.48%
Return on Assets (ttm)
7.74%
Return on Equity (ttm)
15.98%
Revenue (ttm)
3.13B
Net Income Avi to Common (ttm)
359M
Diluted EPS (ttm)
0.66
Balance Sheet and Cash Flow
Total Cash (mrq)
213M
Total Debt/Equity (mrq)
56.27%
Levered Free Cash Flow (ttm)
290.12M